Supriya Lifescience has received Certification of Suitability (CEP) from European Directorate for the Quality of Medicines and HealthCare (EDQM). CEP is for Diphenhydramine Hydrochloride, API in AntiHistamine therapy. This will be an added advantage for Supriya Lifescience in the European market. Global demand for Diphenhydramine Hydrochloride is 1850 tons, of which major demand is in the regulated markets.
Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development.
